Skip to main content
Acta Crystallographica Section E: Crystallographic Communications logoLink to Acta Crystallographica Section E: Crystallographic Communications
. 2019 Apr 2;75(Pt 5):543–546. doi: 10.1107/S2056989019004092

Crystal structure of memantine–carb­oxy­borane

Theppawut I Ayudhya a, Arnold L Rheingold b, Nin N Dingra a,*
PMCID: PMC6505612  PMID: 31110782

The crystal structure of a modified anti-Alzheimer’s drug features O—H⋯O and N—H⋯O hydrogen bonds.

Keywords: crystal structure, memantine-carb­oxy­borane, CORCB, memantine, adamantane

Abstract

The synthesis and crystal structure of the title compound, C13H24BNO2 [systematic name: 3,5-di­methyl­adamantanyl­amine–borane­carb­oxy­lic acid or N-(carb­oxy­boranyl­idene)-3,5-di­methyl­adamantan-1-amine], derived from the anti-Alzheimer’s disease drug memantine is reported. The C—N—B—CO2 unit is almost planar (r.m.s. deviation = 0.095 Å). The extended structure shows typical carb­oxy­lic acid inversion dimers linked by pairwise O—H⋯O hydrogen bonds [O⋯O = 2.662 (3) Å]. The amino group forms a weak N—H⋯O hydrogen bond [N⋯O = 3.011 (3) Å], linking the dimers into [001] chains in the crystal. Highly disordered solvent mol­ecules were treated using the SQUEEZE routine of PLATON [Spek (2015). Acta Cryst. C71, 9–18], which treats the electron density as a diffuse contribution without assignment of specific atom locations. A scattering contribution of 255 electrons was removed. The crystal studied was refined as a two-component twin.

Chemical context  

Memantine is a drug used for the treatment of mild and moderate-to-severe Alzheimer’s disease as an inhibitor for N-methyl-d-aspartate (NMDA) receptors. As a result of its property as a low-affinity, open-channel blocker, memantine does not substanti­ally inter­fere with normal synaptic activity, thereby reducing side effects. This has led to clinical trials for other neurological disorders (Bullock, 2006; Lipton, 2005; Olivares et al., 2012; Parsons et al., 2007). While memantine in its hydro­chloride form is useful in various treatment methods, some modifications were done on this drug to optimize the desired concentration in the system. As a means to preventing drug degradation, memantine has been further processed in a mixture with other compounds (McInnes et al., 2010; Plosker, 2015). The one-week extended release formula by Lyndra Therapeutics is currently under clinical trial phase I (clinicaltrials.gov, NCT03711825). Though efforts to maintain the long-term stability of memantine are underway, chemical modification of the memantine structure itself is rarely reported. Our attempt was to mask the compound with an additional moiety that can be removed under certain conditions, therefore releasing the drug. With this goal, memantine–carb­oxy­borane was synthesized since the carb­oxy­borate group is known to decompose into carbon monoxide and boric acid, leaving the drug mol­ecule itself (Ayudhya et al., 2017, 2018). The single crystal structure of the said compound, (I), was solved and its features are described in this report.

Structural commentary  

The mol­ecular structure of (I) is shown in Fig. 1. The C2–N1–B1–C1/O1/O2 fragment is almost planar (r.m.s. deviation = 0.095 Å) and the C atoms bonded to the B and N atoms take on an anti orientation [C1—B1—N1—C2 = 173.5 (3)°]. The stereogenic centres in the adamantane unit were assigned as C4 S and C8 R in the arbitrarily chosen asymmetric unit but crystal symmetry generates a racemic mixture. The bond lengths [C1—O1 = 1.340 (4), C1—O2 = 1.227 (4) Å] of the carb­oxy­lic acid group are in agreement with the data for related carb­oxy­lic acids and known amine–carb­oxy­boranes (Gavezzotti, 2008; Spielvogel et al., 1980; Vyakaranam et al., 2002; Ayudhya et al., 2017). The C—C—C bond angles of the adamantine cage fall within the expected ranges and the N1—C2 bond length at 1.504 (4) Å is comparable with previously reported values in amino­adamantane structures (Donohue & Goodman, 1967; Chacko & Zand, 1973).graphic file with name e-75-00543-scheme1.jpg

Figure 1.

Figure 1

The mol­ecular structure of (I) with displacement ellipsoids drawn at the 50% probability level.

Supra­molecular features  

A dimer is observed between the two memantine–carb­oxy­borane mol­ecules formed through conventional hydrogen bonding between the carb­oxy­lic acid moieties (Fig. 2). The hydrogen-bond length listed in Table 1 [O1⋯O2 = 2.662 (3) Å] is consistent with the hydrogen-bond geometries found in carb­oxy­borane dimers such as ammonia–carb­oxy­borane [2.668 (2) Å; Spielvogel et al., 1980], mophorline–carb­oxy­borane [2.712 (4) Å; Vyakaranam et al., 2002] and tri­methyl­amine–carb­oxy­borane [2.714 Å; Spielvogel et al., 1976]. In (I), these dimers form an extended structure through N1—H1B⋯O1 links (O1 is the protonated oxygen atom of the carb­oxy­lic acid), to form [001] chains. This motif has also been reported previously in ammonia–carb­oxy­borane, tri­methyl­amine–carb­oxy­borane, di­methyl­amine–carb­oxy­borane and methyl­amine–carb­oxy­borane (Spielvogel et al., 1980). The adjacent dimers shown in Fig. 2 indicates that the planes of the carb­oxy­lic acids are not parallel, but twisted by 76.5° from each other.

Figure 2.

Figure 2

Detail of the hydrogen bonds in (I) showing the carb­oxy­lic acid inversion dimers and N—H⋯O links between dimers.

Table 1. Hydrogen-bond geometry (Å, °).

D—H⋯A D—H H⋯A DA D—H⋯A
O1—H1⋯O2i 0.84 1.82 2.662 (3) 176
N1—H1B⋯O1ii 0.91 2.11 3.011 (3) 171

Symmetry codes: (i) Inline graphic; (ii) Inline graphic.

Assessment of available crystal structures deposited with the Cambridge Structural Database (Version 5.39; Groom et al., 2016) indicates that not all amine–carb­oxy­boranes form dimers during crystallization. While some amine–carb­oxy­boranes described above are dimers, others such as piperidine–carb­oxy­borane and hexa­methyl­ene­tetra­mine–carb­oxy­borane do not form dimers, suggesting that the amine-group inter­action may influence the overall packing (Rana et al., 2002; Ayudhya et al., 2017). The extended structure of (I) is shown in projection down the b- and c-axis directions in Fig. 3 a and 3b, respectively. No other contacts beyond the hydrogen bonds already mentioned are observed in this packing. Although the dimers appear to be parallel in Fig. 3 a, the twisted planes of hydrogen bonds are better represented in Fig. 3 b.

Figure 3.

Figure 3

Packing diagrams of (I): (a) A view from the b axis to show aligned hydrogen-bonding dimers. (b) A view down the c axis to show the twisted planes.

Database survey  

The memantine structure in its free (unprotonated) base form is not found in the literature, although the hydro­chloride salt with water mol­ecules of crystallization has been solved (Lou et al., 2009). Another memantine crystal structure reported was in a clathrate form with cucurbit[7]uril where memantine is completely bound within the cavity (McInnes et al., 2010). However, numerous crystal structures of the adamantane cage and its derivatives in various forms have been reported over many years (Nordman & Schmitkons, 1965; Chacko & Zand, 1973; SiMa, 2009; Glaser et al., 2011).

Synthesis and crystallization  

Memantine, a derivative of adamantine, was first synthesized by Eli Lilly and Company. In an attempt to modify memantine into memantine–carb­oxy­borane, a reaction scheme as shown in Fig. 4 was carried out. Addition of the carb­oxy­borane moiety to memantine was done in a one-step reaction using an amine-exchange process as previously described (Spielvogel et al., 1980). Tri­methyl­amine carb­oxy­borane (117 mg, 1.0 mmol) and memantine (780 mg, 4.4 mmol) were dissolved in tetra­hydro­furan (8.0 ml), and maintained at 328 K for 24 h under a nitro­gen atmosphere. The solution was concentrated by vacuum distillation and the resulting solid was dissolved in di­chloro­methane. The product was precipitated from the solvent by using 15 ml of hexane and the white solid crude product (208 mg) was filtered. This residue was purified by multiple recrystallization in di­chloro­methane/hexane to yield a white solid (15 mg, 6.3%). Crystals suitable for X-ray analysis were prepared by dissolving in toluene and slow cooling of the solution.

Figure 4.

Figure 4

Reaction scheme for the synthesis of (I) through an amine-exchange process.

Refinement  

Crystal data collection and structure refinement details are summarized in Table 2. H atoms were placed in calculated positions (O—H = 0.84, N—H = 0.91 and C—H = 0.98–0.99 Å) and refined as riding with U iso(eq) = 1.5U eq(C-methyl, O) and 1.2U eq(C, N) for all others. The idealized methyl groups at C12 and C13 and the idealized tetra­hedral OH group at O1 were refined as rotating groups. The disordered solvent mol­ecules were treated with the SQUEEZE routine in PLATON (Spek, 2015). The crystal studied was refined as a two-component twin.

Table 2. Experimental details.

Crystal data
Chemical formula C13H24BNO2
M r 237.14
Crystal system, space group Monoclinic, C2/c
Temperature (K) 100
a, b, c (Å) 34.229 (4), 11.1051 (12), 9.2922 (10)
β (°) 96.526 (5)
V3) 3509.3 (7)
Z 8
Radiation type Mo Kα
μ (mm−1) 0.06
Crystal size (mm) 0.32 × 0.30 × 0.10
 
Data collection
Diffractometer Bruker APEXII Ultra
Absorption correction Multi-scan (TWINABS; Bruker, 2012)
T min, T max 0.300, 0.333
No. of measured, independent and observed [I > 2σ(I)] reflections 10740, 10740, 8531
(sin θ/λ)max−1) 0.611
 
Refinement
R[F 2 > 2σ(F 2)], wR(F 2), S 0.062, 0.154, 1.04
No. of reflections 10740
No. of parameters 166
H-atom treatment H atoms treated by a mixture of independent and constrained refinement
Δρmax, Δρmin (e Å−3) 0.94, −0.24

Computer programs: APEX3 and SAINT (Bruker, 2017), SHELXT (Sheldrick, 2015a ), SHELXL2014 (Sheldrick, 2015b ) and OLEX2 (Dolomanov et al., 2009).

Supplementary Material

Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989019004092/hb7806sup1.cif

e-75-00543-sup1.cif (804.1KB, cif)

Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989019004092/hb7806Isup2.hkl

e-75-00543-Isup2.hkl (852.4KB, hkl)

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup4.cdx

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup5.cdx

Graphical Abstract. DOI: 10.1107/S2056989019004092/hb7806sup3.tif

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup6.cml

CCDC reference: 1905840

Additional supporting information: crystallographic information; 3D view; checkCIF report

Acknowledgments

Funding for this research was provided by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant No. P20GM103395. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIH.

supplementary crystallographic information

Crystal data

C13H24BNO2 F(000) = 1040
Mr = 237.14 Dx = 0.898 Mg m3
Monoclinic, C2/c Mo Kα radiation, λ = 0.71073 Å
a = 34.229 (4) Å Cell parameters from 1799 reflections
b = 11.1051 (12) Å θ = 2.9–25.6°
c = 9.2922 (10) Å µ = 0.06 mm1
β = 96.526 (5)° T = 100 K
V = 3509.3 (7) Å3 Plate, colourless
Z = 8 0.32 × 0.30 × 0.10 mm

Data collection

Bruker APEXII Ultra diffractometer 10740 measured reflections
Radiation source: Micro Focus Rotating Anode, Bruker TXS 10740 independent reflections
Double Bounce Multilayer Mirrors monochromator 8531 reflections with I > 2σ(I)
Detector resolution: 8.258 pixels mm-1 θmax = 25.7°, θmin = 1.2°
φ and ω scans h = −41→41
Absorption correction: multi-scan (TWINABS; Bruker, 2012) k = −13→13
Tmin = 0.300, Tmax = 0.333 l = −11→11

Refinement

Refinement on F2 Primary atom site location: dual
Least-squares matrix: full Hydrogen site location: mixed
R[F2 > 2σ(F2)] = 0.062 H atoms treated by a mixture of independent and constrained refinement
wR(F2) = 0.154 w = 1/[σ2(Fo2) + (0.0598P)2 + 6.9836P] where P = (Fo2 + 2Fc2)/3
S = 1.04 (Δ/σ)max < 0.001
10740 reflections Δρmax = 0.94 e Å3
166 parameters Δρmin = −0.24 e Å3
0 restraints

Special details

Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refined as a two-component twin.

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2)

x y z Uiso*/Ueq
O1 0.54884 (6) 0.9933 (2) 1.1021 (3) 0.0296 (6)
H1 0.5259 1.0205 1.0994 0.044*
O2 0.52308 (7) 0.9168 (2) 0.8929 (2) 0.0373 (7)
N1 0.59334 (7) 0.8289 (2) 0.8033 (3) 0.0214 (6)
H1A 0.5763 0.7656 0.7974 0.026*
H1B 0.5825 0.8865 0.7416 0.026*
C9 0.61930 (9) 0.7507 (3) 0.5864 (3) 0.0203 (7)
H9A 0.5993 0.6859 0.5806 0.024*
H9B 0.6077 0.8209 0.5313 0.024*
C2 0.63037 (8) 0.7867 (3) 0.7461 (3) 0.0172 (7)
C10 0.64666 (9) 0.6768 (3) 0.8315 (4) 0.0224 (7)
H10A 0.6267 0.6120 0.8257 0.027*
H10B 0.6536 0.6983 0.9346 0.027*
C8 0.65553 (9) 0.7071 (3) 0.5192 (3) 0.0213 (7)
C11 0.68651 (9) 0.8083 (3) 0.5324 (4) 0.0241 (8)
H11A 0.7103 0.7806 0.4906 0.029*
H11B 0.6759 0.8793 0.4764 0.029*
C6 0.68384 (9) 0.6335 (3) 0.7642 (4) 0.0229 (8)
H6 0.6951 0.5618 0.8193 0.027*
C1 0.55232 (10) 0.9311 (3) 0.9806 (4) 0.0219 (8)
C4 0.69762 (9) 0.8445 (3) 0.6898 (4) 0.0243 (8)
C3 0.66090 (9) 0.8865 (3) 0.7553 (4) 0.0222 (7)
H3A 0.6681 0.9095 0.8578 0.027*
H3B 0.6498 0.9583 0.7023 0.027*
C7 0.67253 (9) 0.5977 (3) 0.6057 (4) 0.0225 (7)
H7A 0.6528 0.5323 0.6002 0.027*
H7B 0.6960 0.5676 0.5639 0.027*
C5 0.71424 (9) 0.7332 (3) 0.7751 (4) 0.0277 (8)
H5A 0.7383 0.7050 0.7354 0.033*
H5B 0.7214 0.7551 0.8780 0.033*
C13 0.64387 (10) 0.6749 (3) 0.3590 (4) 0.0298 (9)
H13A 0.6244 0.6099 0.3522 0.045*
H13B 0.6672 0.6484 0.3157 0.045*
H13C 0.6326 0.7458 0.3071 0.045*
C12 0.72819 (10) 0.9460 (3) 0.6973 (5) 0.0397 (10)
H12A 0.7515 0.9185 0.6543 0.060*
H12B 0.7358 0.9683 0.7988 0.060*
H12C 0.7169 1.0162 0.6438 0.060*
B1 0.59514 (12) 0.8823 (4) 0.9644 (4) 0.0295 (10)
H1C 0.6174 (10) 0.964 (3) 0.966 (4) 0.042 (10)*
H1D 0.6026 (11) 0.810 (3) 1.038 (4) 0.050 (11)*

Atomic displacement parameters (Å2)

U11 U22 U33 U12 U13 U23
O1 0.0235 (12) 0.0335 (13) 0.0342 (14) −0.0008 (11) 0.0140 (12) −0.0136 (11)
O2 0.0334 (14) 0.0620 (17) 0.0167 (12) 0.0240 (13) 0.0038 (12) −0.0048 (13)
N1 0.0202 (14) 0.0169 (13) 0.0280 (15) 0.0034 (11) 0.0062 (12) 0.0043 (12)
C9 0.0237 (18) 0.0150 (16) 0.0222 (17) 0.0018 (13) 0.0026 (15) 0.0029 (15)
C2 0.0149 (16) 0.0182 (16) 0.0190 (16) 0.0039 (13) 0.0043 (14) −0.0018 (14)
C10 0.0236 (18) 0.0213 (17) 0.0230 (17) 0.0000 (14) 0.0062 (15) 0.0018 (15)
C8 0.0238 (18) 0.0177 (16) 0.0227 (18) 0.0022 (14) 0.0046 (15) 0.0007 (15)
C11 0.0225 (18) 0.0206 (17) 0.032 (2) 0.0023 (14) 0.0134 (16) 0.0027 (16)
C6 0.0221 (17) 0.0197 (16) 0.0268 (18) 0.0032 (14) 0.0027 (15) 0.0045 (15)
C1 0.030 (2) 0.0181 (17) 0.0183 (17) 0.0013 (14) 0.0046 (16) 0.0034 (15)
C4 0.0172 (17) 0.0215 (17) 0.035 (2) −0.0027 (14) 0.0082 (16) −0.0072 (16)
C3 0.0238 (18) 0.0193 (17) 0.0235 (17) −0.0012 (14) 0.0024 (15) −0.0002 (15)
C7 0.0214 (18) 0.0187 (16) 0.0287 (17) 0.0021 (14) 0.0079 (16) −0.0043 (16)
C5 0.0170 (17) 0.037 (2) 0.0290 (19) 0.0053 (15) 0.0007 (16) −0.0096 (18)
C13 0.033 (2) 0.033 (2) 0.023 (2) 0.0073 (17) 0.0038 (16) 0.0011 (17)
C12 0.027 (2) 0.036 (2) 0.058 (3) −0.0085 (17) 0.012 (2) −0.012 (2)
B1 0.025 (2) 0.037 (3) 0.028 (2) 0.0001 (19) 0.0062 (18) −0.011 (2)

Geometric parameters (Å, º)

O1—H1 0.8400 C6—H6 1.0000
O1—C1 1.340 (4) C6—C7 1.532 (5)
O2—C1 1.227 (4) C6—C5 1.515 (4)
N1—H1A 0.9100 C1—B1 1.586 (5)
N1—H1B 0.9100 C4—C3 1.530 (4)
N1—C2 1.504 (4) C4—C5 1.541 (4)
N1—B1 1.605 (5) C4—C12 1.535 (4)
C9—H9A 0.9900 C3—H3A 0.9900
C9—H9B 0.9900 C3—H3B 0.9900
C9—C2 1.542 (4) C7—H7A 0.9900
C9—C8 1.530 (4) C7—H7B 0.9900
C2—C10 1.525 (4) C5—H5A 0.9900
C2—C3 1.520 (4) C5—H5B 0.9900
C10—H10A 0.9900 C13—H13A 0.9800
C10—H10B 0.9900 C13—H13B 0.9800
C10—C6 1.557 (4) C13—H13C 0.9800
C8—C11 1.541 (4) C12—H12A 0.9800
C8—C7 1.535 (4) C12—H12B 0.9800
C8—C13 1.539 (5) C12—H12C 0.9800
C11—H11A 0.9900 B1—H1C 1.19 (3)
C11—H11B 0.9900 B1—H1D 1.07 (4)
C11—C4 1.523 (5)
C1—O1—H1 109.5 O2—C1—O1 118.8 (3)
H1A—N1—H1B 106.9 O2—C1—B1 125.8 (3)
C2—N1—H1A 107.3 C11—C4—C3 109.6 (3)
C2—N1—H1B 107.3 C11—C4—C5 108.6 (3)
C2—N1—B1 120.0 (3) C11—C4—C12 109.4 (3)
B1—N1—H1A 107.3 C3—C4—C5 108.2 (3)
B1—N1—H1B 107.3 C3—C4—C12 110.1 (3)
H9A—C9—H9B 108.1 C12—C4—C5 110.8 (3)
C2—C9—H9A 109.5 C2—C3—C4 110.2 (2)
C2—C9—H9B 109.5 C2—C3—H3A 109.6
C8—C9—H9A 109.5 C2—C3—H3B 109.6
C8—C9—H9B 109.5 C4—C3—H3A 109.6
C8—C9—C2 110.7 (2) C4—C3—H3B 109.6
N1—C2—C9 107.2 (2) H3A—C3—H3B 108.1
N1—C2—C10 109.8 (2) C8—C7—H7A 109.7
N1—C2—C3 110.8 (2) C8—C7—H7B 109.7
C10—C2—C9 109.2 (2) C6—C7—C8 109.7 (3)
C3—C2—C9 109.6 (3) C6—C7—H7A 109.7
C3—C2—C10 110.2 (2) C6—C7—H7B 109.7
C2—C10—H10A 110.1 H7A—C7—H7B 108.2
C2—C10—H10B 110.1 C6—C5—C4 109.9 (3)
C2—C10—C6 107.8 (3) C6—C5—H5A 109.7
H10A—C10—H10B 108.5 C6—C5—H5B 109.7
C6—C10—H10A 110.1 C4—C5—H5A 109.7
C6—C10—H10B 110.1 C4—C5—H5B 109.7
C9—C8—C11 108.6 (3) H5A—C5—H5B 108.2
C9—C8—C7 108.3 (3) C8—C13—H13A 109.5
C9—C8—C13 109.6 (3) C8—C13—H13B 109.5
C7—C8—C11 108.6 (3) C8—C13—H13C 109.5
C7—C8—C13 111.4 (3) H13A—C13—H13B 109.5
C13—C8—C11 110.3 (3) H13A—C13—H13C 109.5
C8—C11—H11A 109.4 H13B—C13—H13C 109.5
C8—C11—H11B 109.4 C4—C12—H12A 109.5
H11A—C11—H11B 108.0 C4—C12—H12B 109.5
C4—C11—C8 111.3 (3) C4—C12—H12C 109.5
C4—C11—H11A 109.4 H12A—C12—H12B 109.5
C4—C11—H11B 109.4 H12A—C12—H12C 109.5
C10—C6—H6 109.0 H12B—C12—H12C 109.5
C7—C6—C10 109.7 (3) N1—B1—H1C 104.6 (18)
C7—C6—H6 109.0 N1—B1—H1D 107 (2)
C5—C6—C10 109.5 (3) C1—B1—N1 106.1 (3)
C5—C6—H6 109.0 C1—B1—H1C 109.7 (16)
C5—C6—C7 110.5 (3) C1—B1—H1D 111 (2)
O1—C1—B1 115.4 (3) H1C—B1—H1D 118 (3)

Hydrogen-bond geometry (Å, º)

D—H···A D—H H···A D···A D—H···A
O1—H1···O2i 0.84 1.82 2.662 (3) 176
N1—H1B···O1ii 0.91 2.11 3.011 (3) 171

Symmetry codes: (i) −x+1, −y+2, −z+2; (ii) x, −y+2, z−1/2.

Funding Statement

This work was funded by National Institutes of Health, National Institute of General Medical Sciences grant P20GM103395.

References

  1. Ayudhya, T. I., Pellechia, P. J. & Dingra, N. N. (2018). Dalton Trans. 47, 538–543. [DOI] [PubMed]
  2. Ayudhya, T. I., Raymond, C. C. & Dingra, N. N. (2017). Dalton Trans. 46, 882–889. [DOI] [PubMed]
  3. Bruker (2012). TWINABS. Bruker AXS Inc., Madison, Wisconsin, USA.
  4. Bruker (2017). APEX3 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
  5. Bullock, R. (2006). Alzheimer Dis. Assoc. Disord. 20, 23–29. [DOI] [PubMed]
  6. Chacko, K. K. & Zand, R. (1973). Acta Cryst. B29, 2681–2686.
  7. Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K. & Puschmann, H. (2009). J. Appl. Cryst. 42, 339–341.
  8. Donohue, J. & Goodman, S. H. (1967). Acta Cryst. 22, 352–354.
  9. Gavezzotti, A. (2008). Acta Cryst. B64, 401–403. [DOI] [PubMed]
  10. Glaser, R., Steinberg, A., Šekutor, M., Rominger, F., Trapp, O. & Mlinarić–Majerski, K. (2011). Eur. J. Org. Chem. pp. 3500–3506.
  11. Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta Cryst B72, 171–179. [DOI] [PMC free article] [PubMed]
  12. Lipton, S. A. (2005). Curr. Alzheimer Res. 2, 155–165. [DOI] [PubMed]
  13. Lou, W.-J., Hu, X.-R. & Gu, J.-M. (2009). Acta Cryst. E65, o2191. [DOI] [PMC free article] [PubMed]
  14. McInnes, F. J., Anthony, N. G., Kennedy, A. R. & Wheate, N. J. (2010). Org. Biomol. Chem. 8, 765–773. [DOI] [PubMed]
  15. Nordman, C. E. & Schmitkons, D. L. (1965). Acta Cryst. 18, 764–767.
  16. Olivares, D., Deshpande, V. K., Shi, Y., Lahiri, D. K., Greig, N. H., Rogers, J. T. & Huang, X. (2012). Curr. Alzheimer Res. 9, 746–758. [DOI] [PMC free article] [PubMed]
  17. Parsons, C. G., Stöffler, A. & Danysz, W. (2007). Neuropharmacology, 53, 699–723. [DOI] [PubMed]
  18. Plosker, G. L. (2015). Drugs, 75, 887–897. [DOI] [PubMed]
  19. Rana, G., Vyakaranam, K., Zheng, C., Li, S., Spielvogel, B. F. & Hosmane, N. S. (2002). Main Group Met. Chem. 25, 107–108.
  20. Sheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.
  21. Sheldrick, G. M. (2015b). Acta Cryst. C71, 3–8.
  22. SiMa, W. (2009). Acta Cryst E65, o2492. [DOI] [PMC free article] [PubMed]
  23. Spek, A. L. (2015). Acta Cryst C71, 9–18. [DOI] [PubMed]
  24. Spielvogel, B. F., Das, M. K., McPhail, A. T., Onan, K. D. & Hall, I. H. (1980). J. Am. Chem. Soc. 102, 6343–6344.
  25. Spielvogel, B. F., Wojnowich, L., Das, M. K., McPhail, A. T. & Hargrave, K. D. (1976). J. Am. Chem. Soc. 98, 5702–5703. [DOI] [PubMed]
  26. Vyakaranam, K., Rana, G., Chong, G., Zheng, S. L., Spielvogel, B. F. & Hosmane, N. S. (2002). Main Group Met. Chem. 25, 181–182.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Crystal structure: contains datablock(s) I. DOI: 10.1107/S2056989019004092/hb7806sup1.cif

e-75-00543-sup1.cif (804.1KB, cif)

Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989019004092/hb7806Isup2.hkl

e-75-00543-Isup2.hkl (852.4KB, hkl)

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup4.cdx

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup5.cdx

Graphical Abstract. DOI: 10.1107/S2056989019004092/hb7806sup3.tif

Supporting information file. DOI: 10.1107/S2056989019004092/hb7806Isup6.cml

CCDC reference: 1905840

Additional supporting information: crystallographic information; 3D view; checkCIF report


Articles from Acta Crystallographica Section E: Crystallographic Communications are provided here courtesy of International Union of Crystallography

RESOURCES